12 results about "Membrane bound" patented technology

An object is to provide a method for effectively utilizing byproducts of the production of dairy products. Another object is to provide a method for producing galactosylkojibiose having a superior prebiotic ability. Another object is to provide a solution or composition comprising galactosylkojibiose, wherein at least 80% of galactosylkojibiose is maintained even after heated. A method for producing a composition comprising an oligosaccharide, the method comprising the step of allowing a glucansucrase to act on a composition comprising lactose and sucrose to obtain a composition comprising galactosylkojibiose is provided. It is preferable to use a lactic acid bacterium that constitutively expresses a membrane-bound type glucansucrase. There are provided a solution containing galactosylkojibiose, which has a pH lower than 7, and a composition comprising galactosylkojibiose, wherein when the composition is made into a solution having a solid content concentration of 10 to 80%, the solution has a pH lower than 7.

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and / or TCR function through improvement of cytokine signaling. Disclosed are embodiments of a membrane bound interleukin 15 (IL-15)-IL-15Ralpha sushi domain chimeric receptor. The chimeric receptor may comprise a FAS transmembrane domain or an IL-7 transmembrane domain. Different embodiments of the chimeric receptor have different polypeptide lengths between the IL-15 region and the transmembrane domain.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial infarction, and belongs to the technical field of biology. A research result shows that in a mouse myocardial infarction model, compared with a control group mouse, the death rate of a myocardial cell specific Mboat7 gene overexpressed mouse is reduced, the infarction area is remarkably reduced, and the cardiac function is remarkably improved; the overexpressed Mboat7 gene can relieve mitochondrial damage of myocardial cells under the hypoxia condition and improve the mitochondrial oxidative phosphorylation function. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissues of mice suffering from myocardial infarction. The results show that Mboat7 gene overexpression can relieve myocardial damage after myocardial infarction so as to delay the progress of heart failure, and Mboat7 or an expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating myocardial infarction.

The present invention discloses a membrane-bound L-amino acid deaminase mutant and its application. The membrane-bound L-amino acid deaminase mutant is obtained by mutating the wild-type PM1 enzyme derived from Proteus mirabilis. The amino acid sequence of the wild-type PM1 enzyme is shown in SEQ ID No. 1, and the mutation mode is any one of the following: (1) G259W; (2) D340N. The PM1 enzyme mutant of the present invention is obtained by mutating the wild-type PM1 enzyme derived from Proteus mirabilis. The turnover numbers of the whole cells of the two mutants G259W and D340N for catalyzing L-phenylalanine are increased by 1.3 times and 1.2 times respectively compared with that of the WT.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial hypertrophy, and belongs to the technical field of biology. Research results show that in a mouse cardiac hypertrophy model, compared with a control group mouse, heart weight / body weight, lung weight / body weight, cardiac muscle cell cross sectional area and fibrosis of a cardiac muscle cell specific Mboat7 gene overexpressed mouse are all remarkably reduced, and the cardiac systolic function is remarkably improved; the overexpressed Mboat7 gene can relieve isolated cell myocardial hypertrophy induced by angiotensin II. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissue of a cardiac hypertrophy mouse. The results show that the Mboat7 gene overexpression relieves the disease progress of the pathological cardiac hypertrophy, and the Mboat7 or the expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating the pathological cardiac hypertrophy.

The invention belongs to the field of sewage treatment, and particularly relates to an A / O-MPBR system and a construction method and application thereof. According to the specific technical scheme, the sewage treatment system comprises an A / O treatment system and an MPBR system which are communicated in sequence; the A / O system and the MPBR are mutually independent and communicated in space, and sewage firstly flows through the A / O system to be treated and then enters the MPBR to be treated. And the algae inoculated in the MPBR is Scenedesmus alliensis (Scenedesmus alliensis). The method is characterized in that the algae inoculated in the MPBR are in the form of Scenedesmus alliensis. The invention constructs a microalgae-membrane photosynthetic reactor system capable of continuously feeding and discharging water, and further optimizes operation conditions and screens out microalgae with low nutrition tolerance aiming at the low nutrition background of A / O sewage treatment effluent. The tolerant microalgae and membrane combined photosynthetic reactor is combined for use and is coupled with pilot-scale A / O sewage treatment equipment for operation, so that pollutants are further removed, and the synergistic removal efficiency of antibiotic resistance genes (ARGs) is also remarkably improved.

This invention relates to a method for detecting and predicting chilling injury in peach fruit, comprising the following steps: cutting the fruit pulp into sections and randomly grouping them; subjecting each group of pulp to high-pressure treatment at different pressures; adding a dissociation solution to the pulp in different groups to dissociate membrane-bound polyphenol oxidases in the pulp; and measuring the enzyme activities (B1, B2, B3, B4…B) of the membrane-bound polyphenol oxidases in the pulp treated at different pressures. n The dissociated membrane-bound polyphenol oxidase was activated by adding an activator, and then the enzyme activity C was measured. The activation rates under different high-pressure treatment conditions were B1 / C, B2 / C, B3 / C, B4 / C…B. n / C; Based on the activation rate under high-pressure treatment at different pressures, the pressure value P corresponding to the activation rate discrimination standard value R is calculated. Then, based on the prediction equation between the pressure value P and the storable time, the storable time is calculated. This method can quickly and early detect chilling injury and can also predict the storable time of unknown peach fruits.

The present disclosure is directed to peptide immunogen constructs targeting the extracellular membrane-proximal domain of membrane-bound IgE (or IgE EMPD) and formulations thereof for the treatment of IgE-mediated allergic diseases. The IgE EMPD peptide immunogen constructs have a B cell epitope peptide of more than 20 amino acids, preferably cyclic, linked through an optional spacer to heterologous T helper cell (Th) epitopes derived from pathogen proteins. These peptide immunogen constructs and formulations thereof can stimulate the generation of highly specific antibodies in vaccinated hosts that are directed against the IgE EMPD peptide and are crossreactive with membrane-bound IgE on B lymphocytes committed to IgE secretion. The antibodies induced by the peptide immunogen constructs and formulations thereof in vaccinated hosts can induce apoptosis of IgE-expressing B cells and mediate Antibody Dependent Cellular Cytototoxity (ADCC), resulting in reduction of antigen-specific IgE and total IgE levels in vaccinated hosts to effectively treat IgE-mediated allergic pathology.

Systems, methods and compositions for the production and use of Saccharomyces-generated extracellular vesicles having a membrane-bound nucleic acid transport system adapted to actively transport one or more nucleic acids into the lumen of the vesicle.

This invention presents the CVOM-2 Gram-negative bacterial strain of Caulobacter crescentus, which has a point mutation in the ompA2 gene resulting in the substitution of arginine 351 for alanine, and a null mutation in the rsaA gene that produces outer membrane vesicles (EMVs) with greater efficiency, quantified as the amount of protein / ml of original culture. These EMVs produce a lower inflammatory response than similar preparations obtained from wild-type Escherichia coli cells or cells modified to reduce this response, or even than preparations obtained from a Caulobacter crescentus strain with a wild-type cell envelope.Genetic methods are also presented that allow the modification of these membrane-bound extracellular matrices (MBs), resulting in the presence of a heterologous protein or antigen in soluble form within the vesicle lumen or associated with the vesicle membrane as part of an integral membrane protein. The antigen may be exposed to the lumen or the vesicle surface, or anchored to the outer membrane via lipids. These MBs induce the generation of antibodies against a heterologous protein present within them. MBs also have an adjuvant effect, inducing antibody generation in response to antigen concentrations that would not otherwise elicit this response.

The present application relates to the technical field of biopharmaceuticals, and particularly relates to a siRNA targeting ADAM17 gene based on intestinal barrier repair and application thereof in improving visceral hypersensitivity of IBS. The siRNA silences ADAM17 expression, inhibits abnormal cleavage of IL-10 receptor alpha subunit (IL-10RA) on the membrane of intestinal epithelial cells, maintains the integrity of the membrane-bound IL-10 receptor, restores IL-10 protective signaling, up-regulates tight junction proteins such as ZO-1 and Occludin, reduces intestinal permeability, repairs intestinal mucosal barrier, and finally improves colorectal distension-induced pain threshold and relieves visceral hypersensitivity. Animal model experiments show that the siRNA can significantly reduce the expression of ADAM17 protein in the colon, improve the structure and function of the barrier, and increase the pain threshold, and has application prospects as a new molecular targeted treatment for IBS.

The application relates to a modified PES ultrafiltration membrane modified by a loose anti-pollution coating and a preparation method thereof. The method comprises the following steps: coating a pretreated PES base membrane with a double-monomer aqueous solution containing an amino monomer and a hydroxyl monomer and an isocyanate organic phase solution in sequence, and preparing the modified PES ultrafiltration membrane through an interfacial polymerization reaction at room temperature, and then washing and drying. The space steric hindrance effect of the hydroxyl monomer is utilized to avoid excessive crosslinking of the coating, and a loose three-dimensional hydrophilic crosslinking network containing urea bonds and urethane bonds is constructed in situ on the surface of the base membrane. The preparation method is mild in process and simple in operation, the modified ultrafiltration membrane is stable in coating and base membrane combination, the hydrophilicity and the anti-pollution capability are improved, the water flow permeation resistance is effectively reduced, the defects that the anti-pollution capability and the high flux are difficult to be compatible in traditional modified membranes are overcome, and the method is suitable for industrial application.